, Volume 76, Issue 2, pp 99-104
Date: 23 Jul 2005

Targeted Tumor Cell Death Induced by Autologous Tumor-Specific T Lymphocyte Recognition of Wild-Type p53-Derived Peptides

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


Autologous tumor-specific T lymphocyte (ATTL) lines were derived from the peripheral blood mononuclear cells (PBMC) of a healthy volunteer with human leukocyte antigen (HLA) -A*0201. These lines were achieved using interleukins -1β, -2, -4, and -6 and the p53-based peptide from the 264–272 sequence of the wild-type p53 protein with a strong affinity against HLA-A*0201.

;The frequencies of CD3+, CD4+, and CD8+ lymphocytes were 94–96%, 30–34%, and 69–74%, respectively. ATTLs killed most of the T2 cells pulsed with p53-derived peptide, but not against the T2 cells non-pulsed or pulsed with an irrelevant peptide. ATTLs also killed TKB-14 cells, which have been derived from human glioblastoma multiforme, and exhibited HLA-A*0201 molecule and immunohistochemical accumulation of p53 protein. These cytotoxic activities were inhibited by anti-CD3, anti-CD8, and anti-class I antibodies.

These findings suggested that these ATTL lines might include CTL populations, which could recognize p53-derived peptide on HLA-A*0201 and the p53-based peptide may play as an antigen on HLA-A*0201. When tumor antigens would be more analyzed in the future, ATTL could be induced without the primary-cultured cells from tumor tissue and could be applied for cancer therapy.